|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Income and revenues: | |||||
| Income from purchased receivables under the EIR method | |||||
| Income from purchased receivables under the cost recovery method | |||||
| Revenue from contracts with customers | |||||
| Revenue recognized under units-of-revenue method | |||||
| Total income and revenues | |||||
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Impairment charges (Note 4, Note 5) | |||||
| Arbitration settlement costs (Note 3) | |||||
| Credit losses on purchased receivables | |||||
| Impairment charges (Note 4) | |||||
| Arbitration settlement costs | |||||
| Amortization of intangible assets | |||||
| Total operating expenses | |||||
| Income (loss) from operations | |||||
| Other income (expense), net: | |||||
| Gains on acquisitions | |||||
| Change in fair value of embedded derivative related to RPA | |||||
| Interest expense | |||||
| Other income, net | |||||
| Net income (loss) before tax | |||||
| Income tax (expense) benefit | |||||
| Net income (loss) | |||||
| Comprehensive loss | |||||
| Net income (loss) available to (attributable to) common stockholders, basic | |||||
| Net income (loss) available to (attributable to) common stockholders, diluted | |||||
| Net income (loss) per share available to (attributable to) common stockholders, basic (in dollars per share) | |||||
| Net income (loss) per share available to (attributable to) common stockholders, diluted (in dollars per share) | |||||
| Weighted-average shares used in computing net income (loss) per share available to (attributable to) common stockholders, basic (in shares) | |||||
| Weighted-average shares used in computing net income (loss) per share available to (attributable to) common stockholders, diluted (in shares) | |||||
Loading...
